消化器神経内分泌腫瘍薬物療法のケースファイリング

出版社： 医学と看護社
著者：
発行日： 2017-08-15
分野： 臨床医学：一般  >  癌/腫瘍一般
ISBN： 9784906829781
電子書籍版： 2017-08-15 （第1版第2刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

5,500 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,500 円(税込)

購入する

商品紹介

本書は、消化器に発生した神経内分泌腫瘍に焦点を絞り、患者さんひとりひとりの経過を詳しく検討することで神経内分泌腫瘍の治療を整理しました。希少疾患をまとめるために神経内分泌腫瘍を積極的に診療している日本を代表する4つの施設の症例について治療の選択や経過、ポイントとなる大切な点の解説をわかりやすくまとめました。さらに、コラムとして神経内分泌腫瘍の最近のトピックスを解説。

目次

  • 消化器神経内分泌腫瘍薬物療法のケースファイリング

    ―目次―

    第1章　薬物療法の基本
    　1．神経内分泌腫瘍に対する薬物療法の基本
    　2．神経内分泌がんに対する薬物療法の基本

    第2章　膵神経内分泌腫瘍・がん
    　1．エベロリムスによりPRが得られ、切除し得た
    　　　膵神経内分泌腫瘍の１例
    　2．スニチニブが奏効し、3年治療継続できた1例
    　3．スニチニブを使用した膵神経内分泌腫瘍の1例
    　4．weekly単剤投与のストレプトゾシンにて奏効が得られた１例
    　5．インスリノーマの1例
    　6．同時性肝転移を有するガストリノーマに対して
    　　　集学的治療を行った症例
    　7．様々な薬物療法を施行し得た膵神経内分泌腫瘍の1例
    　8．組織診断がつく前に治療を開始した膵がんの1例
    　9．標準治療不応の膵神経内分泌腫瘍に対して、
    　　　カペシタビン+テモゾロマイド併用療法が奏効した1例
    　10．プラチナ製剤不応の膵神経内分泌がんに対して、
    　　　　エベロリムスが有効であった1例

    第3章　消化管神経内分泌腫瘍・がん
    　1．オクトレオチド療法により病勢制御が得られた
    　　　非機能性の後腸原発神経内分泌腫瘍の１例
    　2．エベロリムス療法により病勢制御が得られた
    　　　後腸原発神経内分泌腫瘍の１例
    　3．治療中、Ki-67値が変化した胃神経内分泌がんの1例
    　4．全身状態不良のため、カルボプラチンベースで
    　　　治療を行った胃神経内分泌がんの1例
    　5．小腸原発神経内分泌がんの1例
    　6．食道神経内分泌がんの1例

    第4章　肝・胆道神経内分泌腫瘍
    　1．最終的に肝原発神経内分泌癌と診断した1例
    　2．胆嚢神経内分泌癌（小細胞癌）に対して
    　　　CBDCA/VP-16が奏効した１例
    　3．肝門部胆管神経内分泌癌に対してプラチナ製剤が奏効した1例

    第5章　診断が困難な神経内分泌腫瘍
    　1．原発不明神経内分泌癌:膵原発？
    　2．肝原発神経内分泌腫瘍が疑われた1例

    第6章　化学療法に伴う合併症
    　1．薬剤性間質性肺炎を繰り返しながらも、
    　　　エベロリムスを継続し、奏効した膵神経内分泌腫瘍の1例
    　2．エトポシド＋シスプラチン療法による発熱性好中球減少症

    コラム
    　神経内分泌腫瘍における病理診断のポイント
    　膵機能性神経内分泌腫瘍の症状と診断
    　ソマトスタチン受容体について
    　ソマトスタチン受容体シンチグラフィ（SRS）とは
    　エベロリムスの薬剤性肺障害対策
    　神経内分泌腫瘍（NET/NEC）の遺伝子異常

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 薬物療法の基本

P.13 掲載の参考文献
1) 日本神経内分泌腫瘍研究会 : 膵・消化管神経内分泌腫瘍 (NET) 診療ガイドライン 2015年 (第1版), 金原出版 ; 2015
 
2) Rinke A, Muller HH, Schade-Brittinger C, et al : Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors : a report from the PROMID Study Group. J Clin Oncol 2009 ; 27 : 4656-63
 
3) Caplin ME, Pavel M, Cwikla JB, et al : Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014 ; 371 : 224-33
PubMed
4) Moertel CG, Lefkopoulo M, Lipsitz S, et al : Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992 ; 326 : 519-23
PubMed
5) Sun W, Lipsitz S, Catalano P, et al : Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors : Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005 ; 23 : 4897-904
PubMed
6) Raymond E, Dahan L, Raoul JL, et al : Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011 ; 364 : 501-13
 
7) Yao JC, Shah MH, Ito T, et al : Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011 ; 364 : 514-23
PubMed
8) Yao JC, Fazio N, Singh S, et al : Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4) : a randomised, placebo-controlled, phase 3 study. Lancet 2016 ; 387 : 968-77
 
9) Strosberg J, El-Haddad G, Wolin E, et al : Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017 ; 376 : 125-35
 
P.18 掲載の参考文献
1) NCCN. org. Neuroendocrine tumor. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) 2017 ; Version 2
 
2) 日本神経内分泌腫瘍研究会 (JNETS) 膵・消化管神経内分泌腫瘍診療ガイドライン作成委員会編 : 膵・消化管神経内分泌腫瘍 (NET) 診療ガイドライン 2015年 (第1版), 金原出版 ; 2015
 
3) Ikeda M, Okuyama H, Takahashi H, et al : Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma. Hepatobiliary Pancreat Sci 2015 ; 22 : 623-7
 
4) Pavel M, Baudin E, Couvelard A, et al : ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012 ; 95 : 157-76
 
5) Yamaguchi T, Machida N, Morizane C, et al : Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci 2014 ; 105 : 1176-81
 
P.19 掲載の参考文献
1) Jensen RT, Cadiot G, Brandi ML, et al : ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms : functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012 ; 95 : 98-119
 
2) Mizuno N, Naruse S, Kitagawa M, et al : Insulinoma with subsequent association of Zollinger-Ellison syndrome. Intern Med 2001 ; 40 : 386-90
 

第2章 膵神経内分泌腫瘍・がん

P.27 掲載の参考文献
1) Yao JC, Shah MH, Ito T, et al : Everolimus for Advanced Pancreatic Neuroendocrine Tumors. N Engl J Med 2011 ; 364 : 514-23
PubMed
2) アフィニトール(R) 適正使用ガイド, ノバルティスファーマ, 東京 ; 2016 : 20-7
 
3) Porta C, Paglino C, Mosca A, et al : Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol 2014 ; 4 : 64
PubMed
4) Stallone G, Infante B, Di Lorenzo A, et al : mTOR inhibitors effects on regulatory T cells and on dendritic cells. J Transl Med 2016 ; 14 : 152
PubMed
5) Yao JC, Pavel M, Lombard-Bohas C, et al : Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors : Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. J Clin Oncol 2016 ; 32 : 3906-13
 
6) Ito T, Okusaka T, Ikeda M, et al : Everolimus for advanced pancreatic neuroendocrine tumours : a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial. Jpn J Clin Oncol 2012 ; 42 : 903-11
PubMed
7) Willemsen AE, Grutters JC, Gerritsen WR, et al : mTOR inhibitor-induced interstitial lung disease in cancer patients : Comprehensive review and a practical management algorithm. Int J Cancer 2016 ; 138 : 2312-21
 
8) Nishino M, Brais LK, Brooks NV, et al : Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors : a radiographic pattern-based approach. Eur J Cancer 2016 ; 53 : 163-70
 
9) Champion L, Stern M, Israel-Biet D, et al : Brief communication : sirolimus-associated pneumonitis : 24 cases in renal transplant recipients. Ann Intern Med 2006 ; 144 : 505-9
 
10) 膵・消化管内分泌腫瘍 (NET) 診療ガイドライン作成委員会編 : 膵・消化管内分泌腫瘍 (NET) 診療ガイドライン 第1版, 金原出版, 東京 ; 2015
 
11) Kulke MH, Shah MH, Benson AB, et al : Neuroendocrine tumors, version 1.2017.https://www.nccn.org/professionals/physician_gls/f_guidelines.asp
 
12) Falconi M, Eriksson B, Kaltsas G, et al : ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology 2016 ; 103 : 153-71
 
13) Doi R : Determinants of surgical resection for pancreatic neuroendocrine tumors. J Hepatobiliary Pancreat Sci 2015 ; 22 : 610-7
 
14) Perysinakis I, Aggeli C, Kaltsas G, et al : Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors : an emerging treatment modality? Hormones (Athens) 2016 ; 15 : 15-22
 
15) Nakamoto S, Nishiyama R, Kaneda T, et al : Conversion Surgery for Initially Unresectable Locally Advanced Pancreatic Cancer Following Gemcitabine plus Nab-Paclitaxel - A Case Report. Gan To Kagaku Ryoho 2017 ; 44 : 173-6
 
P.31 掲載の参考文献
1) Yao JC, Shah MH, Ito T, et al : Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011 ; 364 : 514-23
PubMed
2) Raymond E, Dahan L, Raoul JL, et al : Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011 ; 364 : 501-13
 
3) Ito T, Okusaka T, Nishida T, et al : Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Invest New Drugs 2013 ; 31 : 1265-74
 
P.35 掲載の参考文献
1) Raymond E, Dahan L, Raoul JL, et al : Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011 ; 364 : 501-13
 
2) Ito T, Okusaka T, Nishida T, et al : Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Invest New Drugs 2013 ; 31 : 1265-74
 
3) Kollmannsberger C, Bjarnason G, Burnett P, et al : Sunitinib in metastatic renal cell carcinoma : recommendations for management of noncardiovascular toxicities. Oncologist 2011 ; 16 : 543-53
 
P.41 掲載の参考文献
1) Capurso G, Bettini R, Rinzivillo M, et al : Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease : a systematic review. Neuroendocrinology 2011 ; 93 (4) : 223-9
 
2) Okusaka T, Ueno H, Morizane C, et al : Cytotoxic chemotherapy for pancreatic neuroendocrine tumors. J Hepatobiliary Pancreat Sci 2015 Aug ; 22 (8) : 628-33
 
3) Dilz LM, Denecke T, Steffen IG, et al : Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. Eur J Cancer 2015 ; 51 : 1253
PubMed
4) Pavel M, O'Toole D, Costa F, et al : ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology 2016 ; 103 (2) : 172-85
 
5) Aoki T, Kokudo N, Komoto I, et al : Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors : an analysis of a multi-center survey in Japan. J Gastroenterol 2015 Jul ; 50 (7) : 769-75
 
6) Murray-Lyon IM, Eddleston AL, Williams R, et al : Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet 1968 Oct 26 ; 2 (7574) : 895-8
 
7) Moertel CG, Hanley JA, Johnson LA, et al : Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980 ; 303 : 1189-94
 
8) Moertel CG, Lefkopoulo M, Lipsitz S, et al : Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992 ; 326 : 519-23
PubMed
9) ザノサー適正使用ガイド, ノーベルファーマ (株) ; 2015, (http://www.nobelpharma.co.jp/)
 
10) Broder LE, Carter SK : Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973 ; 79 : 108-18
 
11) Kouvaraki MA, Ajani JA, Hoff P, et al : Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004 ; 22 : 4762
PubMed
12) Turner NC, Strauss SJ, Sarker D, et al : Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 2010 Mar 30 ; 102 (7) : 1106-12
 
13) Krug S, Boch M, Daniel H, et al : Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms-Predictive and Prognostic Markers for Treatment Stratification. PLoS One 2015 Dec 2 ; 10 (12)
 
14) Raj N, Valentino E, Capanu M, et al : Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology : Well Differentiated Versus Poorly Differentiated. Pancreas 2017 Mar ; 46 (3) : 296-301
 
P.47 掲載の参考文献
1) Yao JC, Shah MH, Ito T, et al : Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011 ; 364 : 514-23
PubMed
2) Raymond E, Dahan L, Raoul JL, et al : Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011 ; 364 : 501-13
 
3) Rinke A, Muller HH, Schade-Brittinger C, et al : Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors : a report from the PROMID Study Group. J Clin Oncol 2009 ; 27 : 4656-63
 
4) Caplin ME, Pavel M, Cwikla JB, et al : Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014 ; 371 : 224-33
PubMed
5) Yao JC, Fazio N, Singh S, et al : Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4) : a randomised, placebo-controlled, phase 3 study. Lancet 2016 ; 387 : 968-77
 
6) de Mestier L, Hentic O, Cros J, et al : Metachronous hormonal syndromes in patients with pancreatic neuroendocrine tumors : a case-series study. Ann Intern Med 2015 ; 162 : 682-9
 
7) Service FJ, McMahon MM, O'Brien PC, et al : Functioning insulinoma--incidence, recurrence, and long-term survival of patients : a 60-year study. Mayo Clin Proc 1991 ; 66 : 711-9
 
8) de Herder WW, van Schaik E, Kwekkeboom D, et al : New therapeutic options for metastatic malignant insulinomas. Clin Endocrinol (Oxf) 2011 ; 75 : 277-84
 
9) Cryer PE, Axelrod L, Grossman AB, et al : Evaluation and management of adult hypoglycemic disorders : an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2009 ; 94 : 709-28
 
10) Moertel CG, Frytak S, Hahn RG, et al : Therapy of locally unresectable pancreatic carcinoma : a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5-fluorouracil), and high dose radiation+5-fluorouracil : The Gastrointestinal Tumor Study Group. Cancer 1981 ; 48 : 1705-10
 
11) Hirshberg B, Cochran C, Skarulis MC, et al : Malignant insulinoma : spectrum of unusual clinical features. Cancer 2005 ; 104 : 264-72
 
12) Kvols LK, Buck M, Moertel CG, et al : Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995). Ann Intern Med 1987 ; 107 : 162-8
 
13) Hofeldt FD, Dippe SE, Levin SR, et al : Effects of diphenylhydantoin upon glucose-induced insulin secretion in three patients with insulinoma. Diabetes 1974 ; 23 : 192-8
 
P.54 掲載の参考文献
1) Hosoda W, Sasaki E, Murakami Y, et al : BCL10 as a useful marker for pancreatic acinar cell carcinoma, especially using endoscopic ultrasound cytology specimens. Pathology international 2013 ; 63 : 176-82
PubMed
2) Puli SR, Kalva N, Bechtold ML, et al : Diagnostic accuracy of endoscopic ultrasound in pancreatic neuroendocrine tumors : a systematic review and meta analysis. World J Gastroenterol 2013 ; 19 : 3678-84
 
3) Kwekkeboom DJ, Kam BL, van Essen M, et al : Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010 ; 17 : R53-73
 
4) Bertani E, Fazio N, Botteri E, et al : Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases : possible indications for a multimodal approach. Surgery 2014 ; 155 : 607-14
PubMed
5) Huttner FJ, Schneider L, Tarantino I, et al : Palliative resection of the primary tumor in 442 metastasized neuroendocrine tumors of the pancreas : a population-based, propensity score-matched survival analysis. Langenbecks Arch Surg 2015 ; 400 : 715-23
 
6) Keutgen XM, Nilubol N, Glanville J, et al : Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors. Surgery 2016 ; 159 : 311-8
PubMed
7) 日本神経内分泌腫瘍研究会 (JNETS) : 膵・消化管神経内分泌腫瘍 診療ガイドライン. 2015
 
8) Rinke A, Muller HH, Schade-Brittinger C, et al : Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors : a report from the PROMID Study Group. J Clin Oncol 2009 ; 27 : 4656-63
 
9) Caplin ME, Pavel M, Cwikla JB, et al : Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014 ; 371 : 224-33
PubMed
10) Yao JC, Shah MH, Ito T, et al : Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011 ; 364 : 514-23
PubMed
11) Yao JC, Lombard-Bohas C, Baudin E, et al : Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy : a phase II trial. J Clin Oncol 2010 ; 28 : 69-76
 
12) Turner NC, Strauss SJ, Sarker D, et al : Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 2010 ; 102 : 1106-12
 
13) Weatherstone K, Meyer T : Streptozocin-based chemotherapy is not history in neuroendocrine tumours. Target Oncol 2012 ; 7 : 161-8
PubMed
14) Dilz LM, Denecke T, Steffen IG, et al : Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. Eur J Cancer 2015 ; 51 : 1253-62
 
P.59 掲載の参考文献
1) Yao JC, et al : Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011 Feb 10 ; 364 (6) : 514-23
PubMed
2) アフィニトール添付文書 第11版, ノバルテイス : 2016
 
3) Raymond E, et al : Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011 Feb 10 ; 364 (6) : 501-13
 
4) スーテント添付文書 第10版, ファイザー : 2015
 
P.64 掲載の参考文献
1) 日本膵臓学会 : 膵癌登録報告 2007 Pancreatic Cancer Registry Report 2007/02/20. 第1章 : 組織学的分類. 膵臓 2007 ; 22 : e26-e28
 
2) Ito T, Igarashi H, Nakamura K, et al : Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan : a nationwide survey analysis. J Gastroenterol 2015 ; 50 : 58-64
 
3) Bosman FT, et al : WHO Classification of Tumours of the Digestive System 4th Edition. Lyon, France : IARC Press ; 2010
 
4) Sorbye H, Welin S, Langer SW, et al : Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3) : the NORDIC NEC study. Ann Oncol 2013 ; 24 : 152-60
 
P.69 掲載の参考文献
1) Abood GJ, Go A, Malhotra D, et al : The surgical and systemic management of neuroendocrine tumors of the pancreas. Surg Clin North Am 2009 ; 89 (1) : 249-66, x
PubMed
2) Rinke A, Muller HH, Schade-Brittinger C, et al : Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors : a report from the PROMID Study Group. J Clin Oncol 2009 ; 27 (28) : 4656-63
 
3) Gill GV, Rauf O, MacFarlane IA : Diazoxide treatment for insulinoma : a national UK survey. Postgrad Med J 1997 ; 73 (864) : 640-1
PubMed
4) Yao JC, Shah MH, Ito T, et al : Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011 ; 364 (6) : 514-23
PubMed
5) Raymond E, Dahan L, Raoul JL, et al : Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011 ; 364 (6) : 501-13
 
6) Moertel CG, Lefkopoulo M, Lipsitz S, et al : Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992 ; 326 (8) : 519-23
PubMed
7) Kulke MH, Hornick JL, Frauenhoffer C, et al : O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009 ; 15 (1) : 338-45
 
P.75 掲載の参考文献
1) Yao JC, Shah MH, Ito T, et al : Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011 ; 364 : 514-23
PubMed
2) Sorbye H, Welin S, Langer SW, et al : Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3) : the NORDIC NEC study. Ann Oncol 2013 ; 24 : 152-60
 
3) Fonseca PJ, Uriol E, Galvan JA, et al : Prolonged clinical benefit of everolimus therapy in the management of high-grade pancreatic neuroendocrine carcinoma. Case Rep Oncol 2013 ; 6 : 441-9
 
4) Tang LH, Basturk O, Sue JJ, et al : A Practical Approach to the Classification of WHO Grade 3 (G3) Welldifferentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Am J Surg Pathol 2016 ; 40 : 1192-202
 

第3章 消化管神経内分泌腫瘍・がん

P.80 掲載の参考文献
1) Rinke A, Muller HH, Schade-Brittinger C, et al : Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors : a report from the PROMID Study Group.J Clin Oncol 2009 ; 27 : 4656-63
 
2) Caplin ME, Pavel M, Cwikla JB, et al : Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014 ; 371 : 224-33
PubMed
3) Phan AT, Dasari A, Liyanage N, et al. Tumor response in the CLARINET study of lanreotide depot vs. placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). American Society of Clinical Oncology ; 2016
 
4) Ito T, Igarashi H, Nakamura K, et al : Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan : a nationwide survey analysis. J Gastroenterol 2015 ; 50 : 58-64
 
5) Sclafani F, Carnaghi C, Di Tommaso L, et al : Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry : clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors. Tumori 2011 ; 97 : 620-8
PubMed
6) Neuroendocrine tumors. NCCN Clinical Practice Guidelines in Oncology Version 2. 2017
 
7) Pavel M, O'Toole D, Costa F, et al : ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology 2016 ; 103 : 172-85
 
P.81 掲載の参考文献
1) Kumar U : Cross-talk and modulation of signaling between somatostatin and growth factor receptors. Endocrine 2011 ; 40 : 168-80
 
2) Baldelli R, Barnabei A, Rizza L, et al : Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors : current aspects and new perspectives. Front Endocrinol (Lausanne) 2014 ; 5 : 7
PubMed
3) Shimon I : Somatostatin receptors in pituitary and development of somatostatin receptor subtypeselective analogs. Endocrine 2003 ; 20 : 265-9
 
P.85 掲載の参考文献
1) Chan J, Kulke M : Targeting the mTOR Signaling Pathway in Neuroendocrine Tumors. Curr Treat Options Oncology 2014 ; 15 : 365-79
 
2) Pavel ME, Hainsworth JD, Baudin E, et al : Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2) : a randomised, placebocontrolled, phase 3 study. Lancet 2011 ; 378 : 2005-12
PubMed
3) Yao JC, Fazio N, Singh S, et al : Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4) : a randomised, placebo-controlled, phase 3 study. Lancet 2016 ; 387 : 968-77
 
P.89 掲載の参考文献
1) Janne PA, Yang JC, Kim DW, et al : AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015 ; 372 : 1689-99
 
2) Sorbye H, Welin S, Langer SW, et al : Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3) : the NORDIC NEC study. Ann Oncol 2013 ; 24 : 152-60
 
3) Singh S, Hallet J, Rowsell C, et al : Variability of Ki67 labeling index in multiple neuroendocrine tumors specimens over the course of the disease. Eur J Surg Oncol 2014 ; 40 : 1517-22
 
4) https://www.nccn.org/professionals/physician_gls/f_guidelines.asp
 
5) Yao JC, Fazio N, Singh S, et al : Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4) : a randomised, placebo-controlled, phase 3 study. Lancet 2016 ; 387 : 968-77
 
P.94 掲載の参考文献
1) 膵・消化管神経内分泌腫瘍NET診療ガイドライン 2015, p105-9
 
2) 肺癌診療ガイドライン 2014年版, p165-71
 
3) Skarlos DV, Samantas E, Kosmidis P, et al : Randomized comparison of etoposide-cisplatin vs. etoposidecarboplatin and irradiation in small-cell lung cancer A Hellenic Co-operative Oncology Group study. Ann Oncol 1994 ; 5 : 601-7
 
4) Okamoto H, Watanabe K, Nishiwaki Y, et al : Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol 1999 ; 17 : 3540-5
PubMed
5) Murray N, Grafton C, Shah A, et al : Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer. J Clin Oncol 1998, 16 : 3323-8.
PubMed
6) Okamoto H, Watanabe K, Kunikane H, et al : Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer : JCOG 9702. Br J Cancer 2007 ; 97 : 162-9
PubMed
7) Souhami RL, Spiro SG, Rudd RM, et al : Five-day oral etoposide treatment for advanced small-cell lung cancer : randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 1997 ; 89 : 577-80
PubMed
8) Girling DJ : omparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer : a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. Lancet 1996 ; 348 : 563-6
 
P.100 掲載の参考文献
1) Ito T, Sasano H, Tanaka M, et al : Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010 ; 45 : 234-43
 
2) Scoazec JY, Couvelard A, Monges G, et al : Professional Practices and Diagnostic Issues in Neuroendocrine Tumour Pathology : Results of a Prospective One-Year Survey Among French Pathologists (the PRONET Study). Neuroendocrinology 2016, DOI : 10.1159/000448431
 
3) Yamaguchi T, Machida N, Morizane C, et al : Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Science 2014 ; 105 : 1176-81
 
4) Brenner B, Tang LH, Klimstra DS, et al : Small-Cell Carcinomas of the Gastrointestinal Tract : A Review. J Clin Oncol 2004 ; 22 : 2730-9
 
P.105 掲載の参考文献
1) 膵・消化管神経内分泌腫瘍NET診療ガイドライン 2015, p105-9
 
2) 肺癌診療ガイドライン 2014年版, p165-71
 
3) Terashima T, Morizane C, Hiraoka N, et al : Comparison of chemotherapeutic treatment outcomes of advanced extrapulmonary neuroendocrine carcinomas and advanced small-cell lung carcinoma. Neuroendocrinology 2012 ; 96 : 324-32
 
4) https://cir.ncc.go.jp/search/diagnos/jpn/endocrine.html
 
5) Tachimori Y, Ozawa S, Numasaki H, et al : Comprehensive registry of esophageal cancer in Japan, 2007. Esophagus 2015 ; 12 : 101-29
 
6) Babu Kanakasetty G, Dasappa L, Lakshmaiah KC, et al : Clinicopathological Profile of Pure Neuroendocrine Neoplasms of the Esophagus : A South Indian Center Experience. J Oncol 2016 ; 2016 : 2402417
PubMed
7) Huang Q, Wu H, Nie L, et al : Primary high-grade neuroendocrine carcinoma of the esophagus : a clinicopathologic and immunohistochemical study of 42 resection cases. Am J Surg Pathol 2013 ; 37 : 467-83
 
8) Kubota K, Hida T, Ishikura S, et al : Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202) a randomised phase 3 study. Lancet Oncol 2014 ; 15 : 106-13
PubMed
9) Farooqi AS, Holliday EB, Allen PK, et al : Prophylactic cranial irradiation after definitive chemoradiotherapy for limited-stage small cell lung cancer : Do all patients benefit? Radiother Oncol 2017 ; 122 : 307-12
 
10) Auperin A, Arriagada R, Pignon JP, et al : Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999 ; 341 : 476-84
 
11) Seto T, Takahashi T, Yamanaka T, et al : Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC) : Results of a Japanese randomized phase III trial. J Clin Oncol 2014 ; 32 : 5s (suppl ; abstrt 7503)
 
12) Goto K, Ohe Y, Seto T, et al : A randomized phase III study of cisplatin (CDDP), etoposide (ETOP) and irinotecan versus topotecan as second-line chemotherapy in patients with sensitive relapsed small-cell lung cancer (SCLC) : Japan Clinical Oncology Group study JCOG0605. J Clin Oncol 2014 ; 32 : 5s (suppl ; abstr 7504)
 

第4章 肝・胆道神経内分泌腫瘍

P.112 掲載の参考文献
1) Sorbye H, Welin S, Langer SW, et al : Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3) : the NORDIC NEC study. Ann Oncol 2013 ; 24 : 152-60
 
2) Hicks RJ : Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy. Cancer Imaging 2010 ; 10 : S83-91
 
3) Pavel M, O'Toole D, Costa F, et al : ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology 2016 ; 103 : 172-85
 
4) Strosberg JR, Coppola D, Klimstra DS, et al : The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas 2010 ; 39 : 799-800
 
5) Mitry E, Baudin E, Ducreux M, et al : Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999 ; 81 : 1351-5
PubMed
6) Noda K, Nishiwaki Y, Kawahara M, et al : Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002 ; 346 : 85-91
 
P.118 掲載の参考文献
1) 膵・神経内分泌腫瘍 (NET) 作成委員会 : 膵・消化管神経内分泌腫瘍 (NET) 診療ガイドライン 1.1版
 
2) NCCN Clinical Practice Guideline in Oncology : Neuroendocrine tumors
 
3) Okamoto H, Watanabe K, Nishiwaki Y, et al : Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol 1999 ; 17 : 3540-5
PubMed
4) Okamoto H, Watanabe K, Kunikane H, et al : Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer : JCOG 9702. Br J Cancer 2007 ; 97 : 162-9
PubMed
5) Eltawil KM, Gustafsson BI, Kidd M, et al : Neuroendocrine tumors of the gallbladder : an evaluation and reassessment of management strategy. J Clin Gastroenterol 2010 ; 44 : 687-95
 
6) Mitry E, Baudin E, Ducreux M, et al : Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999 ; 81 : 1351-5
PubMed
7) Noda K, Nishiwaki Y, Kawahara M, et al : Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002 ; 346 : 85-91
 
8) Yamaguchi T, Machida N, Morizane C, et al : Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci 2014 ; 105 : 1176-81
 
9) Ando T, Hosokawa A, Yoshita H, et al : Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma. Gastroenterol Res Pract 2015 ; 2015 : 425876
PubMed
10) von Pawel J, Jotte R, Spigel DR, et al : Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 2014 ; 32 : 4012-9
PubMed
P.124 掲載の参考文献
1) Scoazec JY, et al : Professional Practices and Diagnostic Issues in Neuroendocrine Tumour Pathology : Results of a Prospective One-Year Survey among French Pathologists (the PRONET Study). Neuroendocrinology 2017 ; 105 : 67-76
 
2) Albores-Saavedra J, et al : Carcinoid tumors and small-cell carcinomas of the gallbladder and extrahepatic bile ducts : a comparative study based on 221 cases from the Surveillance, Epidemiology, and End Results Program. Ann Diagn Pathol 2009 ; 13 : 378-83
 
3) 京極典憲, 他 : 胆管原発large cell neuroendocrine carcinomaの1例と文献報告例の検討. 日本消化器外科学会雑誌 2017 ; 50 : 33-42
 
4) Terashima T, et al : Comparison of chemotherapeutic treatment outcomes of advanced extrapulmonary neuroendocrine carcinomas and advanced small-cell lung carcinoma. Neuroendocrinology 2012 ; 96 : 324-32
 
5) Noda K, et al : Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002 ; 346 : 85-91
 
6) Yamaguchi T, et al : Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci 2014 ; 105 : 1176-81
 
7) Zhou H, et al : Duration of chemotherapy for small cell lung cancer : a meta-analysis. PLoS One 2013 ; 8 : e73805
PubMed
P.125 掲載の参考文献
1) Yao JC, Shah MH, Ito T, et al : Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011 ; 364 : 514-23
PubMed
2) Yao JC, Fazio N, Singh S, et al : Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4) : a randomised, placebo-controlled, phase 3 study. Lancet 2016 ; 387 : 968-77
 
3) Saito Y, Gemma A : Current status and DILD in molecular targeted therapies. In J Clin Oncol 2012 ; 17 : 534-41
 
4) Willemsen AE, Grutters JC, Gerritsen WR, et al : mTOR inhibitor-induced interstitial lung disease in cancer patients : Comprehensive review and a practical management algorithm. Int J Cancer 2016 ; 138 : 2312-21
 
5) 日本呼吸器学会薬剤性肺障害の診断・治療の手引き作成委員会 : 薬剤性肺障害の診断・治療の手引き. メディカルレビュー社 ; 2012
 

第5章 診断が困難な神経内分泌腫瘍

P.128 掲載の参考文献
1) Pavlidis N, Pentheroudakis G : Cancer of unknown primary site. Lancet 2012 ; 379 : 1428-35
PubMed
2) Terashima T, Morizane C, Hiraoka N, et al : Comparison of chemotherapeutic treatment outcomes of advanced extrapulmonary neuroendocrine carcinomas and advanced small-cell lung carcinoma. Neuroendocrinology 2012 ; 96 : 324-32
 
3) Brennan SM, Gregory DL, Stillie A, et al : Should extrapulmonary small cell cancer be managed like small cell lung cancer? Cancer 2010 ; 116 : 888-95
 
4) Wong YN, Jack RH, Mak V, et al : The epidemiology and survival of extrapulmonary small cell carcinoma in South East England, 1970-2004. BMC Cancer 2009 ; 9 : 209
 
P.133 掲載の参考文献
1) Song JE, Kim BS, Lee CH : Primary hepatic neuroendocrine tumor : A case report and literature review. World J Clin Cases 2016 ; 4 : 243-7
 
2) Yang K, Cheng YS, Yang JJ, et al : Primary hepatic neuroendocrine tumor with multiple liver metastases : A case report with review of the literature. World J Gastroenterol 2015 ; 21 : 3132-8
 
3) Hu X, Huang Z, Zhang Y, et al : Primary hepatic neuroendocrine tumor : report of one case. Transl Gastroenterol Hepatol 2016 ; 1 : 82
PubMed
P.135 掲載の参考文献
1) Ito T, Igarashi H, Nakamura K, et al : Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan : a nationwide survey analysis. J Gastroenterol 2015 ; 50 : 58-64
 
2) Jiao Y, Shi C, Edil BH, et al : DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011 ; 331 : 1199-203
 
3) Ohki R, Saito K, Chen Y, et al : PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors. Proc Natl Acad Sci U S A 2014 ; 111 : E2404-13
 
4) Aldo S, David K, Katia N, et al : Whole-genome landscape of pancreatic neuroendocrine tumours. Nature 2017 ; 543 : 65-71
 
5) Hijioka S, Hosoda W, Matsuo K, et al : Rb loss and KRAS mutation are predictors of the response to platinum-based chemotherapy in pancreatic neuroendocrine neoplasm with grade 3 : A Japanese multicenter PanNEN-G3 study. Clin Canc Res. in press
 
6) Francis JM, Kiezun A, Ramos AH, et al : Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet 2013 ; 45 : 1483-6
 

第6章 化学療法に伴う合併症

P.139 掲載の参考文献
1) Motzer RJ, Escudier B, Oudard S, et al : Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010 ; 116 : 4256-65
 
2) Yao JC, Shah MH, Ito T, et al : Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011 ; 364 : 514-23
PubMed
3) Tsukamoto T, Shinohara N, Tsuchiya N, et al : Phase III trial of everolimus in metastatic renal cell carcinoma : subgroup analysis of Japanese patients from RECORD-1. Jpn J Clin Oncol 2011 ; 41 : 17-24
PubMed
4) Ito T, Okusaka T, Ikeda M, et al : Everolimus for advanced pancreatic neuroendocrine tumours : a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial. Jpn J Clin Oncol 2012 ; 42 : 903-11
PubMed
5) Nakayama Y, Ikeda M, Kojima M, et al : Successful everolimus treatment in a patient with advanced pancreatic neuroendocrine tumor who developed everolimus-induced interstitial lung disease on two occasions : a case report. Chemotherapy 2013 ; 59 : 74-8
 
6) Porta C, Osanto S, Ravaud A, et al : Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011 ; 47 : 1287-98
 
7) Ohnishi H, Yokoyama A, Yasuhara Y, et al : Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax 2003 ; 58 : 872-5
 
P.145 掲載の参考文献
1) Noda K, Nishiwaki Y, Kawahara M, et al : Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002 ; 346 : 85-91
 
2) Hanna N, Bunn PA Jr, Langer C, et al : Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006 ; 24 : 2038-43
PubMed
3) Lara PN Jr, Natale R, Crowley J, et al : Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer : clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009 ; 27 : 2530-5
PubMed
4) Zatloukal P, Cardenal F, Szczesna A, et al : A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol 2010 ; 21 : 1810-6
PubMed
5) 日本臨床腫瘍学会 : 発熱性好中球減少症 (FN) 診療ガイドライン, 南江堂,東京 ; 2012
 
6) Nesher L, Rolston KV : The current spectrum of infection in cancer patients with chemotherapy related neutropenia. Infection 2014 ; 42 : 5-13
 
7) Klastersky J, Paesmans M : The Multinational Association for Supportive Care in Cancer (MASCC) risk index score : 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer 2013 ; 21 : 1487-95
 
8) Prevention and Treatment of Cancer-Related Infections. NCCN Clinical Practice Guidelines in Oncology Version 2. 2017
 
9) 日本癌治療学会 : G-CSF適正使用ガイドライン. 2013年度版, 第1版, 金原出版, 東京 ; 2013
 
10) Myeloid Growth Factors. NCCN Clinical Practice Guidelines in Oncology Version 2. 2016
 

書評

最近チェックした商品履歴

Loading...